Low Disease Burden Improved Durability of CAR T-Cell Therapy in B-ALL – Cancer Network
Memorial Sloan Kettering Cancer Center |
Low Disease Burden Improved Durability of CAR T-Cell Therapy in B-ALL
Cancer Network Although most adults with relapsed B-cell acute lymphoblastic leukemia (B-ALL) experienced complete remission after treatment with 19-28z chimeric antigen receptor (CAR) T cells, those patients with a low pretreatment disease burden experienced a more … MSK Expertise on Immunotherapy Highlighted in American Association for Cancer Research Annual Meeting Press … Durability of CAR T-cell Therapy Response May Depend on Pretreatment Disease Burden in Leukemia Patients |
